Filing Flows › Fulgent Genetics (FLGT) › Q2 2026
Fulgent Genetics (FLGT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 30, 2026
Fulgent Genetics (FLGT) reported revenue of $85.4M for the second quarter 2026 (Q2 2026), +4% from a year earlier and +20% from the quarter before. Operating margin was -42.2%, net loss $29.7M (34.8% of revenue).
Fulgent Genetics, Q2 2026: revenue $85.4M (+4% year over year), operating margin -42.2%, net loss $29.7M, operating cash flow −$23.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $85.4M | +20% | +4% |
| Operating profit | −$36.1M | — | — |
| Net earnings | −$29.7M | — | — |
| Operating cash flow | −$23.8M | -435% | — |
What changed
Revenue was $85.4M in Q2 2026, up 4% year over year and up 20% from the previous quarter. Laboratory Services was the largest line at 100% of revenue. Laboratory Services added $3.6M year over year (up 4%), 99% of the total change.
Gross margin was 30.1%, down 12.0 points from Q2 2025. Operating costs exceeded revenue by $36.1M, an operating margin of -42.2%. Operating expenses grew 14% against revenue growth of 4%. The fastest-growing cost line was Other operating costs (+140%). The quarter ended with a net loss of $29.7M, wider than the previous quarter's $25.3M loss. Minority interests bore $189K of it: to shareholders the quarter was a loss of $29.5M. Non-operating items added $6.4M, -21% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$23.8M. Non-cash charges added back $7.7M of depreciation and amortization and $8.6M of share-based compensation. Working capital and other items used $10.3M. Capital expenditures of $3.9M exceeded it, leaving free cash flow of −$27.6M.
Questions
What was Fulgent Genetics' revenue in the second quarter 2026?
Fulgent Genetics (FLGT) reported revenue of $85.4M for the second quarter 2026 (Q2 2026), +4% from a year earlier and +20% from the quarter before.
Was Fulgent Genetics profitable in the second quarter 2026?
Operating loss was $36.1M (-42.2% of revenue) and net loss $29.7M.
Source: Fulgent Genetics 10-Q on SEC EDGAR.